Drugs / Ebronucimab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07043283 | Oct 2025 → Feb 2026 | — | Akeso | Completed | No outcome recorded |
| Phase 1 | NCT06641388 | Nov 2024 → Apr 2025 overdue | — | Akeso | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-09-28 | Akeso | Results 康方生物PCSK9单抗（AK102）已开展治疗高胆固醇血症的III期临床研究 akesobio.com ↗
临床研究结果显示，Ebronucimab在治疗高胆固醇血症患者中展现了良好的有效性和安全性特征. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-28 | Akeso | 康方生物PCSK9单抗（AK102）已开展治疗高胆固醇血症的III期临床研究 akesobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ebronucimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07043283 ↗ |
| Route | Subcutaneous | “Ebronucimab subcutaneous injection” NCT06641388 ↗ |